1794091-10-3
Chemical Structure
Virapinib
- CAS No.: 1794091-10-3
- Formula:C26H36N6O
- Molecular Weight:448.60
InChIKey: LUAVWTOZVHIDSI-UHFFFAOYSA-N
SMILES: CC(CC1)CCN1C2=CC=C(C(N3CCC(C4=NC5=C(CCN(C)C5)C(NC)=N4)C3)=O)C=C2
Biological Activity: Virapinib is a macropinocytosis inhibitor with antiviral activity. Virapinib exhibits broad-spectrum antiviral activity against SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, and it enhances Dengue Virus infection. Virapinib blocks viral entry by inhibiting macropinocytosis, reduces syncytium formation in SARS-CoV-2-infected cells, and impairs cellular entry of SARS-CoV-2 variants. Virapinib upregulates the expression of genes related to sterol biosynthesis. Virapinib can be used in studies related to COVID-19, monkeypox, tick-borne encephalitis, and Ebola virus infection[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Virapinib | 98.01% | Virapinib is a macropinocytosis inhibitor with antiviral activity. Virapinib exhibits broad-spectrum antiviral activity against SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, and it enhances Dengue Virus infection. Virapinib blocks viral entry by inhibiting macropinocytosis, reduces syncytium formation in SARS-CoV-2-infected cells, and impairs cellular entry of SARS-CoV-2 variants. Virapinib upregulates the expression of genes related to sterol biosynthesis. Virapinib can be used in studies related to COVID-19, monkeypox, tick-borne encephalitis, and Ebola virus infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Porebski B, et al. Discovery of a novel inhibitor of macropinocytosis with antiviral activity. Mol Ther. 2024;32(9):3012-3024. [Content Brief]
- [2]. Barz, Myriam. Chemical and genetic screening approaches for the discovery of novel treatments. Karolinska Institutet. Thesis. (2025)
- [3]. Wanda Christ, et al. HANTAVIRUSES AND SARS-COV-2: CELL STRESS AND NOVEL ANTIVIRALS.
